1.
Am J Ther
; 31(4): e474-e475, 2024.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38976534
Assuntos
Anticorpos Monoclonais Humanizados , Cetoacidose Diabética , Enterite , Púrpura Trombocitopênica Trombótica , Humanos , Anticorpos Monoclonais Humanizados/efeitos adversos , Cetoacidose Diabética/induzido quimicamente , Cetoacidose Diabética/diagnóstico , Púrpura Trombocitopênica Trombótica/induzido quimicamente , Púrpura Trombocitopênica Trombótica/diagnóstico , Enterite/induzido quimicamente , Enterite/diagnóstico , Enterite/imunologia , Feminino , Masculino , Pessoa de Meia-Idade , Antineoplásicos Imunológicos/efeitos adversos , Diabetes Mellitus Tipo 1/tratamento farmacológico , Diabetes Mellitus Tipo 1/induzido quimicamente
2.
Clin Pract
; 11(4): 694-707, 2021 Sep 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34698139
RESUMO
Obesity and hyperlipidemia are known to be risk factors for various pathological disorders, including various forms of infectious respiratory disease, including the current Coronavirus outbreak termed Coronavirus Disease 19 (COVID-19). This review studies the effects of hyperlipidemia and obesity on enhancing the inflammatory response seen in COVID-19 and potential therapeutic pathways related to these processes. In order to better understand the underlying processes of cytokine and chemokine-induced inflammation, we must further investigate the immunomodulatory effects of agents such as Vitamin D and the reduced form of glutathione as adjunctive therapies for COVID-19 disease.